Park West Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Park West Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-253	Closed	-$2.03M	–	115
2018 Q1	$2.03M	Buy	253 +50	+25%	+$583K	0.09%	83
2017 Q4	$2.68M	Buy	203 +8	+4%	+$94.5K	0.12%	76
2017 Q3	$2.56M	Buy	195 +52	+36%	+$576K	0.15%	60
2017 Q2	$1.27M	Hold	143	–	–	0.07%	61
2017 Q1	$1M	Hold	143	–	–	0.06%	60
2016 Q4	$721K	Hold	143	–	–	0.06%	59
2016 Q3	$912K	Hold	143	–	–	0.08%	57
2016 Q2	$923K	Hold	143	–	–	0.09%	63
2016 Q1	$1.01M	Hold	143	–	–	0.1%	61
2015 Q4	$1.56M	Hold	143	–	–	0.17%	56
2015 Q3	$1.53M	Buy	143 +4	+3%	+$52.6K	0.14%	62
2015 Q2	$2.02M	Sell	139 -1	-0.7%	-$13.9K	0.19%	67
2015 Q1	$1.9M	Hold	140	–	–	0.28%	47
2014 Q4	$1.17M	Hold	140	–	–	0.19%	42
2014 Q3	$1.74M	Hold	140	–	–	0.26%	43
2014 Q2	$1.97M	Buy	140 +1	+0.7%	+$12.3K	0.26%	50
2014 Q1	$2.29M	Buy	+139	New	+$2.6M	0.26%	56

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Park West Asset Management's GLMD Position: Q2 2018 in Review

Park West Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q2 2018, closing a stake of 253 shares — an estimated $2.03M sold.

Park West Asset Management first reported a position in GLMD in Q1 2014 and held it in 17 quarters. The position peaked at $2.68M in Q4 2017. 37 funds tracked by Wall St. Rank hold GLMD as of Q2 2018.

Park West Asset Management reported no remaining Galmed Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Park West Asset Management sold 253 Galmed Pharmaceuticals shares in Q2 2018, an estimated $2.03M.
Park West Asset Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 17 quarters.
Park West Asset Management's Galmed Pharmaceuticals position peaked at $2.68M in Q4 2017.
37 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2018.

Based on Park West Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.